Target intelligence / Profile preview

Protein kinase C eta type (PRKCH)

Target
PRKCH
Molecular classification
Enzyme, Kinase, Serine/threonine-protein kinase
01

Overview

Protein kinase C eta type (PRKCH), also known as PKC-eta, is a calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase belonging to the novel PKC (nPKC) subfamily. It is predominantly expressed in epithelial tissues and the cell nucleus, playing a critical role in regulating cell cycle progression, keratinocyte differentiation, and T-cell-mediated immune responses.\n\nIn oncology, PRKCH exhibits a complex, context-dependent role, acting as an oncogene that promotes cell proliferation and chemoresistance in glioblastoma, breast cancer, and renal cell carcinoma, while also functioning as a tumor suppressor in other settings. Genetic variants of PRKCH, such as the 1425G/A single nucleotide polymorphism, are strongly associated with susceptibility to cerebral infarction and ischemic stroke. Pharmacological targeting of PRKCH is primarily achieved through multi-kinase inhibitors like sotrastaurin and midostaurin, which compete with ATP binding to inhibit its catalytic activity. However, the high structural conservation of the ATP-binding pocket across the PKC family presents significant challenges for achieving isoform selectivity, raising concerns about off-target toxicities and systemic immunosuppression.

Other names
PRKCHPKC-LPKCLPRKCLnPKC-etaprotein kinase C eta
02

Mechanism of action

Inhibition of the kinase catalytic activity by competing with ATP binding, or activation via phorbol esters/diacylglycerol mimics.

03

Biological functions

Signal transductionCell cycleApoptosisCell differentiationCell proliferationImmune response
04

Disease associations

CancerInflammationNeurodegenerative diseaseCardiovascular diseaseStroke
05

Safety considerations

Broad-spectrum PKC inhibition can lead to off-target toxicities due to the highly conserved ATP-binding pocket across PKC isoforms.Immunosuppression or altered immune responses due to its role in T-cell activation.Potential cardiovascular risks or altered vascular integrity.Dual roles in cancer (tumor promotion vs. tumor suppression depending on tissue context) make therapeutic targeting challenging.
06

Interacting drugs

3 more in the full profile.

07

Biomarkers

PRKCH expressionPRKCH promoter methylationPRKCH 1425G/A single nucleotide polymorphism (SNP)rs7161410 variant

Beyond the preview

Go deeper on Protein kinase C eta type (PRKCH).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protein kinase C eta type (PRKCH).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call